CARDIOVASCULAR
hamburger

Journal Articles

The following journal articles help illustrate the clinical evidence for the HeartMate 3™ LVAD with Full MagLev™ Flow Technology:

MOMENTUM 3: A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report

Final 2-yr follow-up of the full cohort (n=1,028 patients) looking at survival at 2 years free of disabling stroke (>3 mRS) or reoperation to replace or remove a malfunctioning device. Mehra, et al. NEJM 2019. DOI: 10.1056/NEJMoa1900486

The data from two-year follow-up of the MOMENTUM 3 full cohort demonstrates:

  • Clinical superiority of the HeartMate 3 LVAS when compared to the HeartMate II LVAS
  • Significantly less frequent rate for pump replacement with HeartMate 3 LVAS
  • Significantly lower rate of stroke and disabling stroke with HeartMate 3 LVAS
  • Significantly lower rate of GI bleeding with HeartMate 3 LVAS
  • Significantly lower rate of pump thrombosis with HeartMate 3 LVAS

Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure — two-year results from the HeartMate 3 CE Mark Study

Schmitto J, Pya Y, Zimpfer D, Krabatsch T, Garbade J, Rao V, Morshuis M, Beyersdorf F, Marasco S, Sood P, Damme L, Netuka I. European Journal of Heart Failure (2018). DOI:10.1002/ejhf.1284.

Two years post-HeartMate 3 implantation, results show expected and acceptable survival, enhanced haemocompatibility, improved patient functional status and quality of life. This corroborates the success of HeartMate 3 since its first-in-man implantation case in Germany.

Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry

Zimpfer D, Gustafsson F, Potapov E, Pya Y, Schmitto J, Berchtold-Herz M, Morshuis M, Shaw S, Saeed D, Lavee J, Heatley G, Gazzola C, Garbade J; on behalf of the ELEVATE Investigators. European Heart Journal (2020) 41, pg. 3801–3809.

Multi-center, multi-national, observational registry. Enrollment of 540 consecutive patients in 26 centers. After 2-year follow-up post-implant ELEVATE demonstrates good 2-year survival and improvement in functional capacity and quality of life with the HeartMate 3 LVAS system in a real-world population. Low stroke rate and pump thrombosis rates are sustained up to 2 years. Low transplant rate (10%).

Publications and Presentation from the MOMENTUM 3 Trial

A comprehensive list of the publications and presentations of analysis from the MOMENTUM 3 IDE trial and CAP study.

Momentum 3 Trial

Two-year results for the HeartMate 3 LVAD

The MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3) investigational device exemption (IDE) clinical study was designed to evaluate the safety and effectiveness of HeartMate 3 Left Ventricular Assist System (LVAS) by demonstrating non-inferiority to the HeartMate II™ LVAS when used for the treatment of advanced refractory left ventricular heart failure.

  • Manuals & Resources
  • Find a HeartMate 3 LVAD Center
  • Customer Service
Indications, Safety & Warnings

MAT-2012515 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.